1.2B4

10070103, human pancreas (islets), Epitheloid

• UNSPSC Code: 41106514

Propiedades

• Nombre del producto: 1.2B4, 10070103, from human pancreas(islets)
• biological source: human pancreas (islets)
• packaging: tube of 5 μg 10070103-DNA-5UG; pkg of vial of cells 10070103-1VL
• growth mode: Adherent
• karyotype: Modal chromosome number 67-71
• morphology: Epitheloid
• products: 1.2B4 cells have been shown to express insulin, glucokinase and IAPP by immunocytochemistry. These cells express the GLUT1 glucose transporter.
• receptors: Not specified
• technique(s): cell culture | mammalian: suitable
• shipped in: dry ice

Descripción

Cell Line Description

1.2B4 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with HuP-T3, a human pancreatic carcinoma cell line (Sigma catalog number 93121055). 1.2B4 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.2B4 cells provide a method of producing pure insulin secreting cells. This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes.

DNA Profile

STR-PCR Data:
Amelogenin: X,Y
CSF1PO: 10
D13S317: 9,11
D16S539: 10,13
D5S818: 10,14
D7S820: 12
THO1: 9
TPOX: 8,12
vWA: 18

Culture Medium

RPMI-1640 + 2 mM Glutamine + 10% FCS / FBS

Subculture Routine

Split sub-confluent cultures (70-80%) 1:2 to 1:6 , i.e., seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. Population doubling approx 20hrs. At confluence 10⁵ cells/cm² can be expected.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Legal Information

Flatt P & McClenaghan N (2004) Insulin producing cell-line US patent number 20040005702 (A1). Also WO0210346 (A2).

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.